Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C8H10N6.5H2O.2H2O4S |
| Molecular Weight | 666.644 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.OS(O)(=O)=O.OS(O)(=O)=O.NNC1=C2C=CC=CC2=C(NN)N=N1.NNC3=C4C=CC=CC4=C(NN)N=N3
InChI
InChIKey=JOPVPUGEMVRMOY-UHFFFAOYSA-N
InChI=1S/2C8H10N6.2H2O4S.5H2O/c2*9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7;2*1-5(2,3)4;;;;;/h2*1-4H,9-10H2,(H,11,13)(H,12,14);2*(H2,1,2,3,4);5*1H2
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Rare liver damage caused by an antihypertensive and anti-arrhythmic agents]. | 1980 Apr 1 |
|
| Side-effects with long-term labetalol: an open study of 251 patients in a single centre. | 1983 |
|
| Action of vasodilating drugs on small and large arteries of hypertensive patients. | 1983 Jul-Aug |
|
| Mode of antihypertensive action of nitrendipine. | 1984 |
|
| Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. | 1996 Oct-Nov |
|
| [Determination of five components in compound hypotensive tablet by HPLC]. | 2004 Aug |
|
| Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. | 2004 Oct |
|
| Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. | 2005 Mar |
|
| Antihypertensive therapy in patients with pre-eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. | 2006 Aug |
|
| Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. | 2007 Jun |
|
| Effects of dihydralazine on renal water and aquaporin-2 excretion in humans. | 2009 |
|
| Emitting species in chemiluminescence reactions with acidic potassium permanganate: a re-evaluation based on new spectroscopic evidence. | 2009 Sep |
|
| Hemodynamic, morphometric and autonomic patterns in hypertensive rats - Renin-Angiotensin system modulation. | 2010 |
|
| Flow-injection chemiluminescence determination of dihydralazine sulfate in serum using luminol and diperiodatocuprate (III) system. | 2010 Jan |
Patents
Sample Use Guides
The influence of a pure afterload reduction on systolic time intervals and various echocardiographic indices was assessed in six healthy volunteers, who underwent a single blind placebo controlled trial of three regimens of intravenous dihydralazine (6.25, 12.5, and 25.0 mg).
Route of Administration:
Intravenous
In Vitro Use Guide
Curator's Comment: In mice bone marrow cells, dihydralazine induced a modest but statistically significant increase over controls in the frequency of sister chromatid exchanges, the rank of potencies being in this case dihydralazine greater than endralazine greater than hydralazine. In the Ames reversion test all three drugs behaved as direct-acting mutagens of low potency, whose activity was not influenced by rat liver nor by mouse liver or lung S-9 fractions. Hydralazine and dihydralazine elicited mixed genetic mechanisms of mutations, while endralazine exclusively induced frameshift errors in Salmonella DNA.
Unknown
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30220456
Created by
admin on Fri Dec 15 18:37:20 GMT 2023 , Edited by admin on Fri Dec 15 18:37:20 GMT 2023
|
PRIMARY | |||
|
3RYP614N6L
Created by
admin on Fri Dec 15 18:37:20 GMT 2023 , Edited by admin on Fri Dec 15 18:37:20 GMT 2023
|
PRIMARY | |||
|
71587248
Created by
admin on Fri Dec 15 18:37:20 GMT 2023 , Edited by admin on Fri Dec 15 18:37:20 GMT 2023
|
PRIMARY | |||
|
70175-06-3
Created by
admin on Fri Dec 15 18:37:20 GMT 2023 , Edited by admin on Fri Dec 15 18:37:20 GMT 2023
|
PRIMARY | |||
|
100000076099
Created by
admin on Fri Dec 15 18:37:20 GMT 2023 , Edited by admin on Fri Dec 15 18:37:20 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
